<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "Triple negative breast cancer" AND "therapy"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Targeting the Id1-Kif11-Aurka axis in triple negative breast cancer using combination therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/760686v1">Link</a></p><p><b>Date:</b> 2019-09-11</p><p><b>Authors:</b> Reshma Murali ... Radhika Nair</p><p><b>Downloads:</b> 172</p><p><b>Relevance Score:</b> 1.0</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Evidence points to breast cancer following a hierarchical model, with Cancer Stem Cells (CSCs) driving critical phenotypes of the bulk tumor.  Chemoresistant CSCs are not an abstract concept but have clinical consequences as they drive relapse and ultimately lead to mortality in patients, making it imperative to understand how these subpopulations of cells survive.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32015106">Link</a></p><p><b>Date:</b> 2020-02-05</p><p><b>Authors:</b> Gaofeng Xiong ...  Ren Xu</p><p><b>Journal:</b> Proc. Natl. Acad. Sci. U.S.A.</p><p><b>IF (7 or above):</b> 9.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Increased expression of extracellular matrix (ECM) proteins in circulating tumor cells (CTCs) suggests potential function of cancer cell-produced ECM in initiation of cancer cell colonization.  Here, we showed that collagen and heat shock protein 47 (Hsp47), a chaperone facilitating collagen secreti ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/215954v1">Link</a></p><p><b>Date:</b> 2017-11-08</p><p><b>Authors:</b> Aurélie S Cazet ... Alexander Swarbrick</p><p><b>Downloads:</b> 764</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The cellular and molecular basis of stromal cell recruitment, activation and crosstalk in carcinomas is poorly understood, limiting the development of targeted anti-stromal therapies.  In mouse models of triple negative breast cancer (TNBC), Hh ligand produced by neoplastic cells reprogrammed cancer-associated fibroblast (CAF) gene expression, driving tumor growth and metastasis.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/192385v2">Link</a></p><p><b>Date:</b> 2017-09-22</p><p><b>Authors:</b> Annie Wang ... Lei Xie</p><p><b>Downloads:</b> 392</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Existing drug discovery process follows a reductionist model of 'one-drug-one-gene-one-disease,' which is not adequate to tackle complex diseases that involve multiple malfunctioned genes.  The availability of big omics data offers new opportunities to transform the drug discovery process into a new paradigm of systems pharmacology that focuses on designing drugs to target molecular interaction networks instead of a single gene.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: STAT3 and GR cooperate to drive basal-like triple negative breast cancer gene expression and proliferation.</h4><p><a href="https://www.biorxiv.org/content/10.1101/730606v1">Link</a></p><p><b>Date:</b> 2019-08-09</p><p><b>Authors:</b> Megan E Conway ... Katherine E Varley</p><p><b>Downloads:</b> 265</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Breast cancers can be divided into subtypes with different prognoses and treatment responses based on global gene expression differences.  Luminal breast cancer gene expression and proliferation are driven by the transcription factors Estrogen Receptor alpha (ER), FOXA1 and GATA3.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: The inhibitory effects of butein on cell proliferation and TNF-α-induced CCL2 release in racially different triple negative breast cancer cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/596080v1">Link</a></p><p><b>Date:</b> 2019-04-01</p><p><b>Authors:</b> Patricia Mendonca ... Karam F.A. Soliman</p><p><b>Downloads:</b> 148</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Breast cancer drug resistance is the leading cause of cancer-related mortality in women, and triple negative breast cancer (TNBC) is the most aggressive subtype, affecting African American women more aggressively compared to Caucasians.  Of all cancer-related deaths, 15 to 20% are associated with inflammation, where proinflammatory cytokines have been implicated in the tumorigenesis process.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Application of Polymersomes Engineered to Target P32 Protein for Detection of Small Breast Tumors in Mice</h4><p><a href="https://www.biorxiv.org/content/10.1101/187716v3">Link</a></p><p><b>Date:</b> 2017-09-12</p><p><b>Authors:</b> Lorena Simón-Gracia ... Tambet Teesalu</p><p><b>Downloads:</b> 561</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Triple negative breast cancer (TNBC) is the deadliest form of breast cancer and its successful treatment critically depends on early diagnosis and therapy.  The multi-compartment protein p32 is overexpressed and present at cell surfaces in a variety of tumors, including TNBC, specifically in the malignant cells and endothelial cells, and in macrophages localized in hypoxic areas of the tumor.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/209288v1">Link</a></p><p><b>Date:</b> 2017-10-26</p><p><b>Authors:</b> Zhixian Liu ... Xiaosheng Wang</p><p><b>Downloads:</b> 758</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Triple-negative breast cancer (TNBC) is a high-risk malignancy due to its high capacity for invasion and lack of targeted therapy.  Immunotherapy continues to demonstrate efficacy in a variety of cancers, and thus may be a promising strategy for TNBC given the limited therapeutic options currently available for TNBC.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: B7-H1(PD-L1) confers chemoresistance through ERK and p38 MAPK pathway in tumor cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/308601v1">Link</a></p><p><b>Date:</b> 2018-04-25</p><p><b>Authors:</b> Xiaosheng Wu ... Haidong Dong</p><p><b>Downloads:</b> 646</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Development of resistance to chemotherapy and immunotherapy is a major obstacle in extending the survival of patients with cancer.  Although several molecular mechanisms have been identified that can contribute to chemoresistance, the role of immune checkpoint molecules in tumor chemoresistance remains underestimated.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: TP53 mutations promote immunogenic activity in breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/354779v1">Link</a></p><p><b>Date:</b> 2018-06-24</p><p><b>Authors:</b> Zhixian Liu ... Xiaosheng Wang</p><p><b>Downloads:</b> 611</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no any immunotherapeutic strategy for breast cancer (BC).  Thus, it is important to discover biomarkers for identifying the BC patients responsive to immunotherapy.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: An atlas of infiltrated B-lymphocytes in breast cancer revealed by paired single-cell RNA-sequencing and antigen receptor profiling</h4><p><a href="https://www.biorxiv.org/content/10.1101/695601v1">Link</a></p><p><b>Date:</b> 2019-07-15</p><p><b>Authors:</b> Qingtao Hu ... Yu Zhang</p><p><b>Downloads:</b> 596</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> While it has been well-recognized that T-cell mediated adaptive cellular immunity plays important roles in cancer immune response and tumor control, the roles of B lymphocytes in tumor development and therapy have only been proposed until recently, and are still mostly controversial.  To gain mechanistic insights into the origin and dynamics of tumor infiltrated immune cells, especially B lymphocytes, we combine single-cell RNA-sequencing and antigen receptor lineage analysis to characterize a large number of triple-negative breast cancer (TNBC) infiltrated immune cells and present a comprehensive atlas of infiltrated B-lymphocytes in TNBC, the most aggressive breast cancer subtype.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Evolution of an intratumoral ecology susceptible to successive treatment in breast cancer xenografts</h4><p><a href="https://www.biorxiv.org/content/10.1101/249797v2">Link</a></p><p><b>Date:</b> 2018-01-18</p><p><b>Authors:</b> Hyunsoo Kim ... Jeffrey H. Chuang</p><p><b>Downloads:</b> 494</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The processes by which tumors evolve are essential to the efficacy of treatment, but quantitative understanding of intratumoral dynamics has been limited.  Although intratumoral heterogeneity is common, quantification of evolution is difficult from clinical samples because treatment replicates cannot be performed and because matched serial samples are infrequently available.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Reduction of LOXL2-mediated H3K4 oxidation increases chromatin accessibility and promotes chemosensitivity of triple-negative breast cancer cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/416495v1">Link</a></p><p><b>Date:</b> 2018-09-13</p><p><b>Authors:</b> J.P. Cebrià-Costa ... S. Peiró</p><p><b>Downloads:</b> 272</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function.  We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenographs (PDXs) than those from other breast cancer subtypes.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Paradigm of Vanadium pentoxide nanoparticle-induced autophagy and apoptosis in triple-negative breast cancer cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/810200v1">Link</a></p><p><b>Date:</b> 2019-10-18</p><p><b>Authors:</b> Parvathy Radhakrishna Pillai Suma ... Ramapurath S Jayasree</p><p><b>Downloads:</b> 207</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chemo-resistance remains the main hurdle to cancer therapy, challenging the improvement of clinical outcomes in cancer patients.  Therefore, exploratory studies to address chemo-resistance through various approaches are highly rewarding.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: ADAR1 editing dependency in triple-negative breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.31.928911v1">Link</a></p><p><b>Date:</b> 2020-02-02</p><p><b>Authors:</b> Che-Pei Kung ... Jason D Weber</p><p><b>Downloads:</b> 175</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer.  Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: miR-425 suppresses EMT and inhibits the development of TNBC (triple-negative breast cancer) by targeting TGF-β 1/SMAD 3 signaling pathway</h4><p><a href="https://www.biorxiv.org/content/10.1101/477877v1">Link</a></p><p><b>Date:</b> 2018-11-26</p><p><b>Authors:</b> Yingping Liu ... Jinglong Chen</p><p><b>Downloads:</b> 149</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: EMT has the crucial effect on the progression and metastasis of tumor.  This work will elucidate the role of miR-425 in EMT and development of TNBC.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype</h4><p><a href="https://www.biorxiv.org/content/10.1101/858969v1">Link</a></p><p><b>Date:</b> 2019-11-29</p><p><b>Authors:</b> Alejandro J. Español ... María E. Sales</p><p><b>Downloads:</b> 104</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Triple negative tumors are more aggressive than other breast cancer subtypes and there is a lack of specific therapeutic targets on them.  Since muscarinic receptors have been linked to tumor progression, we investigated the effect of metronomic therapy employing a traditional anti-cancer drug, paclitaxel plus muscarinic agonists at low doses on this type of tumor.</p></div></td></div><td></td></tr></table></div><hr></div></body></html>